Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 5.3% – Still a Buy?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shot up 5.3% during mid-day trading on Tuesday . The company traded as high as $22.95 and last traded at $22.6940. 1,206,498 shares were traded during mid-day trading, a decline of 80% from the average session volume of 6,042,610 shares. The stock had previously closed at $21.55.

Analyst Ratings Changes

SRPT has been the subject of a number of research reports. Piper Sandler lifted their target price on Sarepta Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a research note on Thursday, October 30th. Robert W. Baird reduced their price objective on Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating for the company in a research report on Tuesday, November 4th. Mizuho raised Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $19.00 to $26.00 in a research report on Wednesday, November 5th. Leerink Partners raised their target price on Sarepta Therapeutics from $12.00 to $15.00 and gave the company a “market perform” rating in a research note on Tuesday, September 9th. Finally, Wall Street Zen lowered shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Nine analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and six have given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $33.68.

Sarepta Therapeutics Stock Up 3.2%

The firm’s fifty day moving average is $20.90 and its two-hundred day moving average is $20.75. The firm has a market cap of $2.33 billion, a price-to-earnings ratio of -7.39 and a beta of 0.54. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.95 and a quick ratio of 1.79.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.15). The company had revenue of $399.36 million for the quarter, compared to analyst estimates of $331.51 million. Sarepta Therapeutics had a negative net margin of 11.25% and a negative return on equity of 4.85%. The firm’s quarterly revenue was down 14.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.62 EPS. On average, sell-side analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SRPT. Ancora Advisors LLC increased its holdings in shares of Sarepta Therapeutics by 150.0% in the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 300 shares in the last quarter. Brooklyn Investment Group lifted its holdings in shares of Sarepta Therapeutics by 450.4% during the first quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 590 shares during the last quarter. Banque Transatlantique SA acquired a new position in shares of Sarepta Therapeutics in the 1st quarter valued at $44,000. iSAM Funds UK Ltd purchased a new position in Sarepta Therapeutics in the 3rd quarter worth about $25,000. Finally, Byrne Asset Management LLC acquired a new stake in Sarepta Therapeutics during the 3rd quarter worth about $33,000. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.